Product
NNC0365-3769
Aliases
NNC0365-3769 (Mim8)
3 clinical trials
4 indications
Indication
Hemophilia AIndication
Hemophilia A with InhibitorsIndication
Healthy Control ParticipantsIndication
Haemophilia AClinical trial
A Multinational, Open-label, Randomised, Controlled Study to Investigate Efficacy and Safety of NNC0365-3769 (Mim8) in Adults and Adolescents With Haemophilia A With or Without InhibitorsStatus: Recruiting, Estimated PCD: 2024-03-11
Clinical trial
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Subcutaneous Doses of NNC0365-3769 (Mim8) in Healthy Subjects and in Subjects With Haemophilia A With or Without Factor VIII InhibitorsStatus: Completed, Estimated PCD: 2023-10-06
Clinical trial
A Study to Demonstrate Bioequivalence of a Single Subcutaneous Administration of NNC0365-3769 (Mim8) With the DV3407-C1 Pen Injector Versus a Syringe and Enhanced Cartridge in Healthy Male ParticipantsStatus: Completed, Estimated PCD: 2023-09-12